Proven effective oral medication
for Age-Related Macular Degeneration

Daily oral treatment to halt AMD progression
and help recover lost vision

Formulated by a California vision-care researcher, AMD Stopper is a newly discovered oral treatment requiring no injections which has been shown to stop Age-Related Macular Degeneration in its tracks

What is AMD?

Age-Related Macular Degeneration is a chronic eye disease and the most common cause of severe loss of eyesight among people 50 and older. An estimated 300 to 400 million people worldwide suffer from this disorder which affects the central vision.
As AMD progresses, a part of the retina called the macula is damaged. In advanced stages, people lose their ability to drive, to see faces, and to read text. In its early stages, AMD may have no signs or symptoms, so people may not suspect they have it.

The most common symptoms of age-related macular degeneration include:
• Blurry or fuzzy vision
Difficulty recognizing familiar faces
Straight lines appear wavy
• A dark, empty area or blind spot in the center of vision
• Loss of central vision, which is necessary for driving, reading, recognizing faces and performing close-up work

Finally, relief for millions of AMD sufferers

There is no cure for AMD and consequently a ready global market for any treatment which can promise to slow or reverse the disease. As many as 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050. Age is a prominent risk factor for age-related macular degeneration. The chance of getting advanced age-related macular degeneration increases from 2% for those ages 50-59, to nearly 30% for those over the age of 75.
AMD Stopper, Inc. is a newly organized company which holds the formulas, patent applications, and intellectual property rights to the formula developed by an eyecare researcher to treat Age- Related Macular Degeneration.

AMD Stopper is the sole owner and licensee of this groundbreaking oral medication and will either be manufactured by the Company or licensed to an FDA-certified drug manufacture under the supervision of the scientists, Ophthalmologists, and physicians employed or under contract.

Manufacturers of eyecare medications are invited to contact

AMD Stopper for licensing and partnering opportunities

To bring AMD Stopper to market* AMD Stopper is seeking to partner with pharmaceutical manufacturers in Mexico, Latin America, Europe, and North America to prepare and achieve marketing approval. Of particular interest is entering the Mexican market where an estimated 15 million are suffering from the blinding effects of AMD.

James Kraushaar
AMD Stopper